@article {38726,
	title = {Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-αMSH and [161Tb]Tb-crown-αMSH},
	journal = {Nuclear Medicine and Biology},
	volume = {136-137},
	year = {2024},
	abstract = {<p>Targeted radionuclide therapy is established as a highly effective strategy for the treatment of metastatic tumors; however, the co-development of suitable imaging companions to therapy remains significant challenge. Theranostic isotopes of terbium (149Tb, 152Tb, 155Tb, 161Tb) have the potential to provide chemically identical radionuclidic pairs, which collectively encompass all modes of nuclear decay relevant to nuclear medicine. Herein, we report the first radiochemistry and preclinical studies involving 155Tb- and 161Tb-labeled crown-αMSH, a small peptide-based bioconjugate suitable for targeting melanoma.<br />\&nbsp;</p>},
	doi = {https://doi.org/10.1016/j.nucmedbio.2024.108925},
	author = {L. Wharton and S.W. McNeil and C. Zhang and G. Engudar and M. Van de Voorde and J. Zeisler and H. Koniar and S. Sekar and Z. Yuan and P. Schaffer and V. Radchenko and M. Ooms and P. Kunz and F. B{\'e}nard and H. Yang}
}
